Warsaw - Delayed Quote PLN
Bioceltix S.A. (BCX.WA)
106.60
+3.60
+(3.50%)
At close: 5:02:21 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
0
0
0
0
10.80
Cost of Revenue
1,380.51
1,038.08
699.99
853.86
478.55
Gross Profit
-1,380.51
-1,038.08
-699.99
-853.86
-467.75
Operating Expense
14,373.03
12,977
8,254.92
3,550.03
1,910.78
Operating Income
-15,753.54
-14,015.08
-8,954.92
-4,403.90
-2,378.52
Net Non Operating Interest Income Expense
112.77
244.99
-67.20
-17.37
12.73
Pretax Income
-15,590.47
-13,692.82
-8,967.48
-4,356.10
-2,365.79
Tax Provision
56.73
-5.27
-46.10
41.52
-17.04
Net Income Common Stockholders
-15,647.20
-13,687.55
-8,921.38
-4,397.62
-2,348.75
Diluted NI Available to Com Stockholders
-15,647.20
-13,687.55
-8,921.38
-4,397.62
-2,348.75
Basic EPS
-3.83
-3.49
-2.67
-1.39
-0.95
Diluted EPS
-3.83
-3.49
-2.67
-1.39
-0.95
Basic Average Shares
4,139.93
3,919.12
3,336.07
3,160.87
3,286.79
Diluted Average Shares
4,139.93
3,919.12
3,336.07
3,160.87
3,286.79
Total Operating Income as Reported
-15,724.61
-14,015.08
-8,900.28
-4,338.73
-2,447.76
Total Expenses
15,753.54
14,015.08
8,954.92
4,403.90
2,389.32
Net Income from Continuing & Discontinued Operation
-15,647.20
-13,687.55
-8,921.38
-4,397.62
-2,348.75
Normalized Income
-15,670.63
-13,687.55
-8,975.74
-4,450.40
-2,348.75
Interest Income
229.42
278.64
0
6.90
29.75
Interest Expense
116.64
33.65
31.51
22.95
17.02
Net Interest Income
112.77
244.99
-67.20
-17.37
12.73
EBIT
-15,473.83
-13,659.17
-8,935.98
-4,333.15
-2,348.77
EBITDA
-14,988.34
-13,224.37
-8,490.59
-3,956.17
-2,125.86
Reconciled Cost of Revenue
1,380.51
1,038.08
699.99
853.86
478.55
Reconciled Depreciation
485.49
434.80
445.39
376.98
89.02
Net Income from Continuing Operation Net Minority Interest
-15,647.20
-13,687.55
-8,921.38
-4,397.62
-2,348.75
Total Unusual Items Excluding Goodwill
28.93
0
54.64
65.17
0
Total Unusual Items
28.93
0
54.64
65.17
0
Normalized EBITDA
-15,017.27
-13,224.37
-8,545.23
-4,021.33
-2,125.86
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
5.50
0
0.28
12.38
0
12/31/2020 - 11/8/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IMR.BE AC Immune SA
1.6940
+12.93%
NXOA.BE Nicox SA
0.2260
-0.88%
ABRT.CN Albert Labs International Corp.
0.0050
0.00%
8EM.BE Editas Medicine Inc
1.5245
-1.33%
5CV.HA CureVac NV
3.8120
-0.78%
BT1.BE Bone Therapeutics SA
0.0018
0.00%
2LB.MU Iovance Biotherapeutics Inc
1.5644
0.00%
GYX.F Futura Medical plc
0.0895
-0.56%
0M4.F Mersana Therapeutics, Inc.
0.2672
+0.23%
P0F.F Egetis Therapeutics AB (publ)
0.3285
-5.06%